Buprevet 0.3 mg/ml Solution for Injection for Dogs and Cats
Active ingredient: Buprenorphine
Form
Injection
Species
Manufacturer
VetViva Richter GmbH
VMD MA No.
57446/4007
What it's used for
Potentiation of the sedative effects of centrally-acting agents. Cats: Post-operative analgesia.
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Buprenorphine
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Buprevet 0.3 mg/ml Solution for Injection for Dogs and Cats — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Cats:
Post-operative analgesia.
possible. The use of suitably calibrated measuring equipment is recommended.
Dogs: Post-operative analgesia, potentiation of the sedation
Cats: Post-operative analgesia
10 - 20 micrograms of buprenorphine per kg bodyweight (i.e. 0.3 - 0.6 ml of the
veterinary medicinal product per 10 kg bodyweight).
For further pain relief the dose may be repeated if necessary:
Dogs: Either after 3 - 4 hours with 10 micrograms of buprenorphine per kg
bodyweight or after 5 - 6 hours with 20 micrograms of buprenorphine per
kg bodyweight.
Cats: Once, after 1 - 2 hours with 10 - 20 micrograms of buprenorphine per kg
bodyweight.
While sedative effects are present by 15 minutes after administration, analgesic
activity becomes apparent after approximately 30 minutes. To ensure that analgesia
AN: 01641/2025 & 01643/2025
is present during surgery and immediately on recovery, the veterinary medicinal
product should be administered preoperatively as part of premedication.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may
show variable responses. Therefore, the response of individual animals should be
monitored and subsequent doses should be adjusted accordingly. In some cases,
repeat doses may fail to provide additional analgesia. In these cases, consideration
should be given to using a suitable injectable NSAID.
excipients.
Do not administer by the intrathecal or peridural route.
Do not use pre-operatively for Caesarian section (see section 3.7).
AN: 01641/2025 & 01643/2025
Rare
(1 to 10 animals / 10 000
animals treated):
Hypertension, Tachycardia;
Sedation
.
Undetermined frequency
(cannot be estimated from the
available data):
Hypersalivation;
Bradycardia;
Hypothermia, Dehydration;
Agitation;
Miosis;
Respiratory depression.
When used to provide analgesia. May occur at dose levels higher than those
recommended.
Cats:
Common
(1 to 10 animals / 100 animals
treated):
Mydriasis
;
Behavioural disorder
1,2
.
Rare
(1 to 10 animals / 10 000
animals treated):
Sedation
.
Undetermined frequency
(cannot be estimated from the
available data):
Respiratory depression.
Will usually resolve within 24 hours.
Signs of euphoria (excessive purring, pacing, rubbing).
When used to provide analgesia. May occur at dose levels higher than those
recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Special precautions for safe use in the target species:
Buprenorphine may cause respiratory depression and as with other opioid drugs,
care should be taken when treating animals with impaired respiratory function or
animals that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the veterinary medicinal product.
Safety has not been fully evaluated in clinically compromised cats.
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
The safety of buprenorphine has not been demonstrated in animals less than 7
weeks of age.
Repeat administration earlier than the recommended repeat interval suggested in
section 3.9 is not recommended.
Long-term safety of buprenorphine in cats has not been investigated beyond 5
consecutive days of administration.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied.
Use of the veterinary medicinal product in the above circumstances should only be in
accordance with the benefit-risk assessment by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
As buprenorphine has opioid activity, care should be taken to avoid self-injection.
Buprenorphine may be absorbed systemically on exposure to mucous membranes.
The veterinary medicinal product may cause skin or eye irritation if contact occurs.
Following eye, skin or mouth contact, wash the affected area thoroughly with water.
Seek medical advice if irritation persists.
In case of accidental self-injection or ingestion, seek medical advice immediately and
show the package leaflet or the label to the physician. Naloxone should be available
in case of accidental self-injection. Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 01641/2025 & 01643/2025
centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that
when buprenorphine is employed within the normal therapeutic range, standard
doses of opioid agonist may be administered before the effects of the former have
ended without compromising analgesia. However, it is recommended that
buprenorphine is not used in conjunction with morphine or other opioid-type
analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or
butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadolone,
atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol,
sevoflurane, thiopental and xylazine. When used in combination with sedatives,
depressive effects on heart rate and respiration may be augmented.
This veterinary medicinal product does not contain an antimicrobial preservative.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Other Products Containing Buprenorphine
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
We may earn a small commission if you purchase through these links, at no extra cost to you.
Related Medications
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.